A rheumatoid arthritis drug developed by Genentech proved to be effective in benefitting patients who have Covid-19-associated pneumonia, according to new late-stage clinical trial data.

Sanofi and Regeneron said results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.

Sanofi announced disappointing results from a Phase III study of intravenously dosed Kevzara (sarilumab) in which hospitalized Covid-19 patients failed to meet primary and secondary endpoints.

British drugmaker AstraZeneca started testing an antibody-based cocktail for the prevention and treatment of Covid-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.

Novartis announced that the Phase III COMBI-I trial of the company’s experimental checkpoint inhibitor spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to hit the primary endpoint in melanoma.

As the world is eagerly awaiting news of an effective and safe vaccine against Covid-19, several companies are moving ahead testing therapeutic antibodies against the disease.

U.K.-based Celleron Therapeutics signed a licensing agreement with Swiss pharma giant Roche for the worldwide rights to the cancer drug emactuzumab, a monoclonal antibody directed against colony-stimulating factor 1 (CSF-1R) expressed on macrophages.

Vir Biotechnology Inc. plans to start a mid-to-late stage trial of the company’s Covid-19 drug candidate in August, as drugmakers across the globe rush to find treatments for the highly infectious virus.

Researchers at the University of California, San Francisco (UCSF) synthesized a molecule inspired by llama antibodies called nanobodies that could neutralize SARS-CoV-2, the virus that causes Covid-19.

Omeros Corp.’s experimental treatment helped six patients with acute respiratory distress syndrome caused by Covid-19 recover and get discharged from the hospital, sending the drug developer’s shares up 60%.